AJCC 8th Edition Major Updates
in Cancer Staging:
Implications for OPC treatment?
AHNS Transoral Robotic Surgery Course
April, 2017
Kelly Michele Malloy, MD, FACS
,• I have no conflicts of interest to disclose related to the
content of this presentation.
,AJCC TNM Cancer Staging Manual, 8thEdition
• “[We] have been proactive to incorporate new relevant
genomic markers, for example, in breast cancer and
oropharyngeal cancer, to build and empower the traditional
concepts of staging of cancer.”
– Mahul B. Amin, MD, FCAP, Editor
• Dr. Amin added the transition to include new molecular
markers is a significant development in this manual, and he
believes it “will only grow exponentially in future staging
efforts to allow staging to be very contemporary, relevant and
applicable in clinical care of individual patients,” he said
– AJCC Press Release, October 2016
, AJCC TNM Cancer Staging Manual, 8thEdition
• Originally intended to apply to all new cancers in 2017,
implementation was delayed until January 1, 2018.
• Allow for infrastructure to be built to accommodate the
changes.
– This is not as nimble an environment for change
• Big data
• Electronic medical records
• “Clinicians will continue to use the latest information for
patient care, including scientific content of the 8th Edition
Manual. All newly diagnosed cases through December
31st, 2017 should be staged with the 7th edition.”
• “The time extension will allow all partners to develop and
update protocols and guidelines and for software vendors to
develop, test, and deploy their products in time for the data
collection and implementation of the 8th edition in 2018.”
in Cancer Staging:
Implications for OPC treatment?
AHNS Transoral Robotic Surgery Course
April, 2017
Kelly Michele Malloy, MD, FACS
,• I have no conflicts of interest to disclose related to the
content of this presentation.
,AJCC TNM Cancer Staging Manual, 8thEdition
• “[We] have been proactive to incorporate new relevant
genomic markers, for example, in breast cancer and
oropharyngeal cancer, to build and empower the traditional
concepts of staging of cancer.”
– Mahul B. Amin, MD, FCAP, Editor
• Dr. Amin added the transition to include new molecular
markers is a significant development in this manual, and he
believes it “will only grow exponentially in future staging
efforts to allow staging to be very contemporary, relevant and
applicable in clinical care of individual patients,” he said
– AJCC Press Release, October 2016
, AJCC TNM Cancer Staging Manual, 8thEdition
• Originally intended to apply to all new cancers in 2017,
implementation was delayed until January 1, 2018.
• Allow for infrastructure to be built to accommodate the
changes.
– This is not as nimble an environment for change
• Big data
• Electronic medical records
• “Clinicians will continue to use the latest information for
patient care, including scientific content of the 8th Edition
Manual. All newly diagnosed cases through December
31st, 2017 should be staged with the 7th edition.”
• “The time extension will allow all partners to develop and
update protocols and guidelines and for software vendors to
develop, test, and deploy their products in time for the data
collection and implementation of the 8th edition in 2018.”
